
Evidence analysis
Strengthening public health emergency operations centres in Europe through exchange of good practices
Strengthening Public Health Emergency Operations Centres in Europe Through Exchange of Good Practices What is established A three-day training workshop held in Ljubljana from October 5–7, 2026, focused on enhancing the capacities of Public Health Emergency Operations Centres…
Read →
Evidence analysis
F1’s Rwanda Race Could Be Bad News for Rights
F1’s Rwanda Race and Its Implications for Human Rights: An Evidence Dossier What is Established Formula One has signed a 10-year agreement to host a Grand Prix race in Rwanda, starting in the early 2030s. This move marks…
Read →
Evidence analysis
Syria: Women Barred from Defense, Security Colleges
What is established In October 2026, Syrian authorities introduced admissions rules barring women from most academic programs at two new state universities focused on defense and security. These restrictions prevent women from enrolling in land, naval, and air…
Read →
Evidence analysis
Romanian Institutions Bought Banned Russian Cybersecurity Software
Accountability in the Romanian Procurement of Banned Russian Cybersecurity Software This evidence dossier examines the revelations reported by OCCRP on October 16, 2026, regarding Romanian public institutions' purchases of cybersecurity products from Kaspersky, a Russian company, despite legal…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Neuzafy, filgrastim, Status: Opinion
New Medicines and Opinions: Neuzafy (filgrastim) What is established Neuzafy is a biosimilar medicinal product containing filgrastim, a recombinant granulocyte colony-stimulating factor (G-CSF). Filgrastim works by stimulating the bone marrow to increase production and maturation of neutrophils, a…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Kizfizo, temozolomide, Status: Opinion
Kizfizo (Temozolomide): New European Medicines Agency Opinion on Treatment for Glioma This dossier examines the recent positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) regarding Kizfizo, a new formulation of…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Fovlussea, ranibizumab, Ophthalmologicals, Status: Opinion
What is established On 15 October 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the granting of marketing authorization for Fovlussea, a biosimilar drug to ranibizumab. Ranibizumab is…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Remicade, infliximab, Date of authorisation: 13/08/1999, Revision: 70, Status: Authorised
What is established Remicade (active substance infliximab) is a monoclonal antibody medicine authorised in the European Union since 1999. It is used primarily as an anti-inflammatory treatment in several autoimmune diseases where inflammation is pathological, including rheumatoid arthritis,…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Idelvion, albutrepenonacog alfa, Date of authorisation: 11/05/2016, Revision: 14, Status: Authorised
Health & Science Evidence Dossier: Idelvion (albutrepenonacog alfa) for Haemophilia B What is established Idelvion is a medicinal product authorized for use in the European Union to prevent and treat bleeding episodes in patients with haemophilia B, an…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 16/01/2009, Revision: 54, Status: Authorised
What is established Stelara (ustekinumab) is a monoclonal antibody drug authorized in the European Union since 2009 for the treatment of several inflammatory diseases including moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis.…
Read →